Dr. Sirjana Shrestha

Dr. Srijana Shrestha is currently working as a Senior Kayachikitsa Consultant in National Ayurveda Research and Training Centre, Kirtipur, Kathmandu, Nepal. Dr. Shrestha has done Doctor of Medicine (M.D.) in Ayurveda (Kayachikitsa) from Ayurveda Campus, Institute of Medicine, Tribhuvan University, Kathmandu in 2018 and Bachelor of Ayurvedic Medicine and Surgery (BAMS) from Ayurveda Campus, Institute of Medicine, Tribhuvan University, Kathmandu in 2004.

Major publications:

1. Efficacy of Ayurvedic herbal formulation and Ayurvedic herbo-mineral formulation in hypothyroidism patients, published on November 2021 in Journal of Ayurvedic and Herbal Medicine 2021; 7(4): 237-246, DOI: 10.31254/jahm.2021.7405.
2. A retrospective study of overview of patients visited at Kayachikitsa department’s OPD at TUACTH, published on November 2021 in Journal of Ayurveda Campus2(1):27-30, DOI: 51648/jac.30.
3. Review on Hypothyroidism as per Ayurveda, published on February 2021 in The HealerJournal 2(1):74-79, DOI: 51649/healer.46.
4. The Effectiveness of Taalishadi Churna Compared with Sitopaladi Churna in the Management of Kasa, published on February 2021 in International Journal of Research in AYUSH and Pharmaceutical Sciences, DOI: 47070/ijraps.v4i12.99.
5. The Effectiveness of Goksuradi Guggulu and Varunadi Kwath with Goksuradi Guggulu in the Management of Mutrasmari w.s.r. to Urolithiasis, published on January 2021 in International Journal of Research in AYUSH and Pharmaceutical Sciences, DOI: 47070/ijraps.v4i11.98.
6. Study of Patient flow and treatments done in Patients Visiting Striroga and Prasutitantra (Gynae/Obs) Department of T.U. Ayurveda Campus Teaching Hospital (TUACTH), published on October 2020 in Journal of Ayurveda Campus1(1):26-28, DOI: 51648/jac.8.
7. Effect of Ayurvedic classical medicines in Kaphaja Kasa: A case report, published on September 2020 in Journal of Ayurveda Campus1(1):64-67, DOI: 51648/jac.21.
8. Efficacy and safety of Trikgud as an add-on medicine in uncontrolled type 2 diabetes mellitus (T2DM) patients with metformin monotherapy: A randomized controlled trial, published on August 2022, DOI: 10.15406/ijcam.2022.15.00613.